Atopic Dermatitis, Atopic Dermatitis (AD), Atopic Dermatitis / Eczema, Atopic Dermatitis (Eczema), Atopic Dermatitis Patients, Atopic Dermatitis, Unspecified
Conditions
Keywords
Registry, Dupilumab, Abrocitinib, Upadacitinib, JAK-inhibitor, Atopic dermatitis, Baricitinib
Brief summary
The goal of this observational registry is to characterize the clinical features, severity, treatments, and outcomes of patients with atopic dermatitis in Costa Rica receiving systemic and advanced therapies in routine clinical practice. The main questions it aims to answer are: What are the demographic and clinical characteristics of patients with moderate-to-severe atopic dermatitis treated in specialized dermatology centers in Costa Rica? What treatments are used in real-world practice and how do they impact disease severity and patient-reported outcomes over time? Participants with atopic dermatitis receiving systemic or advanced therapies as part of their usual medical care will be followed longitudinally, with collection of clinical severity scores, treatment patterns, and outcomes during routine visits.
Detailed description
This is a national, multicenter, observational registry of patients with atopic dermatitis treated in dermatology referral centers in Costa Rica. The registry aims to document demographic characteristics, disease history, severity, comorbidities, treatment patterns, and longitudinal outcomes in patients receiving systemic immunosuppressants, biologic agents, or other advanced therapies in routine clinical practice. Data will be collected prospectively and retrospectively from medical records and routine clinical assessments, including validated severity indices (e.g., EASI, SCORAD, DLQI), treatment exposure, adverse events, and therapeutic response over time. The registry will allow evaluation of real-world effectiveness, safety, and treatment persistence, as well as characterization of moderate-to-severe atopic dermatitis in the Costa Rican population. This registry does not modify clinical management; all treatments are prescribed according to physician judgment and standard care.
Interventions
DRUGAbrocitinib
This registry specifically focuses on patients with moderate-to-severe atopic dermatitis receiving systemic immunosuppressive or biologic therapies in real-world clinical practice in Costa Rica. Unlike clinical trials or other dermatologic registries, this study captures routine-care treatment patterns, including conventional systemic agents and newer targeted biologics used according to physician judgment without protocol-mandated interventions. The registry uniquely characterizes disease severity, treatment response, and quality-of-life outcomes in the Costa Rican population across multiple centers, enabling evaluation of effectiveness, safety, and persistence of advanced therapies in everyday practice rather than controlled research settings.
DRUGUpadacitinib
This registry specifically focuses on patients with moderate-to-severe atopic dermatitis receiving systemic immunosuppressive or biologic therapies in real-world clinical practice in Costa Rica. Unlike clinical trials or other dermatologic registries, this study captures routine-care treatment patterns, including conventional systemic agents and newer targeted biologics used according to physician judgment without protocol-mandated interventions. The registry uniquely characterizes disease severity, treatment response, and quality-of-life outcomes in the Costa Rican population across multiple centers, enabling evaluation of effectiveness, safety, and persistence of advanced therapies in everyday practice rather than controlled research settings.
DRUGBaricitinib
This registry specifically focuses on patients with moderate-to-severe atopic dermatitis receiving systemic immunosuppressive or biologic therapies in real-world clinical practice in Costa Rica. Unlike clinical trials or other dermatologic registries, this study captures routine-care treatment patterns, including conventional systemic agents and newer targeted biologics used according to physician judgment without protocol-mandated interventions. The registry uniquely characterizes disease severity, treatment response, and quality-of-life outcomes in the Costa Rican population across multiple centers, enabling evaluation of effectiveness, safety, and persistence of advanced therapies in everyday practice rather than controlled research settings.
BIOLOGICALDupilumab
This registry specifically focuses on patients with moderate-to-severe atopic dermatitis receiving systemic immunosuppressive or biologic therapies in real-world clinical practice in Costa Rica. Unlike clinical trials or other dermatologic registries, this study captures routine-care treatment patterns, including conventional systemic agents and newer targeted biologics used according to physician judgment without protocol-mandated interventions. The registry uniquely characterizes disease severity, treatment response, and quality-of-life outcomes in the Costa Rican population across multiple centers, enabling evaluation of effectiveness, safety, and persistence of advanced therapies in everyday practice rather than controlled research settings.
Sponsors
Caja Costarricense de Seguro Social
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Clinical diagnosis of atopic dermatitis according to accepted diagnostic criteria * Moderate-to-severe disease requiring systemic or advanced therapy * Receiving systemic immunosuppressive, biologic, or other advanced treatment as part of routine care * Evaluated in participating dermatology centers in Costa Rica * Available clinical records with baseline and follow-up information
Exclusion criteria
* Lack of sufficient clinical data for severity or treatment assessment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in atopic dermatitis severity over time | 5 years | Measured using validated clinical severity scales EASI (Eczema Area and Severity Index) |
| Treatment patterns in moderate-to-severe atopic dermatitis | 5 years | Type and duration of systemic or advanced therapies prescribed in real-world practice during the observation period. |
| Patient-reported quality of life | 5 years | Change in Dermatology Life Quality Index (DLQI) scores over time during treatment. |
Countries
Costa Rica
Contacts
CONTACTDaniel E Barquero-Orias, Dermatologist
Outcome results
None listed